Compare Neurocrine Biosciences Inc (NBIX) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

PALL (Aberdeen Physical Palladium Shares ETF) trades at $25.15, showing minimal daily movement with a 0.16% gain. Technical indicators show a bullish trend with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. The ETF recently underwent a 1:5 stock split effective May 18, 2026, adjusting share structure while maintaining exposure to physical palladium.

PALL offers exposure to palladium's supply-demand dynamics amid current price weakness, with analysts viewing the 47% decline from January 2026 highs as a potential buying opportunity. Key risks include Federal Reserve policy uncertainty and industrial demand fluctuations. The ETF's physical backing provides direct commodity exposure, though palladium's volatility requires careful risk management.